New York State Teachers Retirement System Sells 142,670 Shares of Pfizer Inc. (NYSE:PFE)

New York State Teachers Retirement System decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 3.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,666,604 shares of the biopharmaceutical company's stock after selling 142,670 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Pfizer worth $118,252,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Rialto Wealth Management LLC purchased a new stake in Pfizer in the fourth quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new position in shares of Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC boosted its stake in shares of Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer during the fourth quarter valued at $30,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PFE shares. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. UBS Group lifted their price target on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Price Performance

Pfizer stock traded up $0.08 during mid-day trading on Monday, hitting $24.27. The stock had a trading volume of 44,590,813 shares, compared to its average volume of 41,386,005. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $137.98 billion, a P/E ratio of 17.59, a P/E/G ratio of 0.88 and a beta of 0.57. The firm's 50 day moving average is $23.46 and its 200 day moving average is $24.84.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.09%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.